potential systemic side-effects, mainly occurring after sc injection, long-term duration and sometimes limited treatment effect, which all affect therapy safety and treatment adherence/patient compliance.
1,2
Encapsulation of allergens into nanoparticles (NPs) might be one strategy for improvement of AIT due to the following reasons: NPs may serve as a carrier system for proteins, peptides, or DNA molecules and may also have adjuvant effects. [3] [4] [5] There is not yet routinely available. 2 An oral administration route for food AIT seems natural, but it brings along additional requirements for the nanocarrier; as the cargo needs to be delivered to the intestine, NPs have to be resistant to gastric acid and need to cross the epithelial barrier and the mucosa to reach the lamina propria. 3 Another important feature of NPs depending on the design (size, charge, particle shape) is improved and accelerated cellular uptake, which in turn may allow fewer treatments and may increase convenience. Allergen-coated NPs, on the other hand, facilitate cross-linking of IgE on the surface and thereby activation of the immune cells and are usually used for investigation of prophylactic allergen vaccinations in mice. Empty NPs without allergen encapsulation or coating have also been tested for allergy treatment, mostly in a prophylactic approach, and show promising results enabling the restoration of a balanced Th1 and Th2 immune response due to their adjuvant activity. 3, 5, 6 There are thousands of publications using particles (mainly NPs, but also microparticles/microspheres depending on their size measured in nanometer or micrometer) as carrier systems for drug delivery with focus on vaccination strategies against cancer, infectious diseases, or autoimmune diseases. 5, [7] [8] [9] Considerable less research has been undertaken for the use of NPs in AIT 3, 6 ,10 which will be discussed below separated into biodegradable and nonbiodegradable NPs.
| BIODEGRADABLE N ANOSTRUCTURES
Biodegradable nanostructures can be divided into synthetic polymers (polyesters), natural polymers (polypeptides, polysaccharides), liposomes, and virus-like particles ( Figure 2 ). An overview for the use of biodegradable NPs in AIT including their composition and manufacturing method is shown in Table 1A ,B.
F I G U R E 1
Comparison of allergenspecific immunotherapy with soluble allergen and with allergen encapsulated in nanoparticles (NPs)
| Synthetic polymers
The most popular polyesters used in drug delivery are poly(lactic acid) and poly(lactic-co-glycolic acid) (PLGA), also abbreviated PLG (poly(lactide-co-glycolide)), which degrade under biological conditions via enzymatic hydrolysis. However, a rather long degradation time of up to 24 months together with the acidic degradation products that may result in inflammation at higher concentrations, and the difficulty of derivatization are the main drawbacks of these materials. To overcome these limitations, copolymers of basic character to neutralize generated acidity or copolymers to allow derivatization can be utilized. [11] [12] [13] Encapsulation of different allergens or allergen DNA in PLGA NPs or PLGA microparticles was investigated by several groups. In general, intranasal or oral immunization of mice with these particles led to a Th1 immune response (reduced allergen-specific IgE and increased allergen-specific IgG2a levels) and expression of IL-10 preventing mice against sensitization. [14] [15] [16] [17] [18] [19] In vitro experiments
showed that dendritic cells (DCs) matured after particle uptake and were more effective in T-cell activation. 19 There are also some reports showing a therapeutic effect in sensitized mice treated with PLGA NPs or PLGA microparticles which induced a conversion from Th2 to Th1 responses and an upregulation of regulatory T cells leading to decreased lung inflammation and mucus secretion, reduced numbers of total cells and eosinophils in bronchoalveolar lavage (BAL) fluid as well as decreased anaphylaxis. [20] [21] [22] [23] [24] [25] [26] In either cases, co-encapsulation of Th1 activator CpG-ODN or the immunosuppressor rapamycin enhanced the therapeutic or prophylactic effects. [18] [19] [20] 25, 26 Poly(e-caprolactone) (PCL) is another popular polymer for biodegradable drug delivery systems because of the biocompatibility of this aliphatic polyester, its high permeability, and low glass transition temperature. The latter may enable fast disassembly and therefore release of the cargo molecules upon temperature rise to body temperature. 27 In ovalbumin (OVA)-sensitized mice, treatment with OVA-PCL elicited similar OVA-specific IgG1 levels as treatment with OVA alum but lower levels of IgE together with lower production of serum histamine, leading to a higher survival rate after allergen challenge due to reduced anaphylaxis. Poly(c-glutamic acid) (c-PGA) is formed by bacterial fermentation and can be used as a carrier and adjuvant simultaneously.
In vitro stimulation of DCs from allergic donors with a mixture of a c-PGA graft copolymer and grass pollen extract enhanced proliferation and IL-10 production of autologous memory T cells. 32 Furthermore, c-PGA copolymer NPs within L-leucine microcarriers for dry F I G U R E 2 Overview of biodegradable nanostructures used in allergen-specific immunotherapy (AIT) hypoallergenicity. 36 Proteins can also be coupled to the surface of polysaccharides by cyanogen halides. 37 Grass pollen or cat allergens coupled to sepharose microbeads by this method induced a mixed allergen-specific Th1/Th2 immune response when injected into mice and did not lead to granulomatous tissue reactions compared to alum-adsorbed allergens. Furthermore, prophylactic and therapeutic immunotherapy with these carbohydrate-based particles prevented/ reduced airway hyperreactivity and eosinophils in BAL fluid, and induced a shift from IgE toward IgG2a production. In vitro, the particles were internalized by human DCs leading to an upregulation of CD86, IL-8, and TNF-a. [38] [39] [40] [41] Chitin was reported to upregulate Th1 immune responses. Oral or intranasal administration of chitin particles during sensitization resulted in a decrease of IgE, lung eosinophil numbers, and airway hyperreactivity. In vitro restimulation of spleen cells showed a decrease of Th2 cytokines along with an increased production of IFN-c. 42, 43 Similarly, immunization of mice with grass pollen extract conjugated to the adjuvant alginate isolated from the cell walls of brown algae led to higher allergen-specific IgG (no specific subclasses are shown) and lower IgE production compared to alum-adsorbed allergens. 44 In clinical trials, immunotherapy with alginate-conjugated allergens increased IgG1 and IgG4 levels while allergen-specific IgE was reduced. 45, 46 Gelatin consists of denatured and hydrated collagen derived from animals. Treatment of allergic horses with gelatin NP-based CpG increased IL-10 expression and caused a significant decrease of allergic symptoms (respiratory effort, nasal discharge, tracheal secretion, and viscosity). 47 Chitosan is a linear amino-functional polysaccharide derived from chitin by deacetylation and is known from different drug delivery approaches. 48, 49 Due to its cationic character after protonation, it has been used to complex DNA or proteins in several murine studies, and successful prophylactic and therapeutic protection against allergic diseases was demonstrated with OVA, peanut, and house dust mite protein or DNA.
These NPs as well as allergen-free chitosan NPs loaded with IFN-c or TGF-ß expressing DNA induce Th1 or Treg responses. [50] [51] [52] [53] [54] [55] [56] [57] [58] In vitro, allergen-loaded chitosan NPs led to an enhanced uptake, processing, and antigen presentation by DCs, a reduction of cellular inflammation in human keratinocytes, and a reduced IFN-c and IL-10 secretion by human PBMC from allergic donors.
58,59
T A B L E 1 (Continued) responses as well as eosinophilia compared to free allergen. 66 Similarly, liposomes which were generated from dipalmitoylphosphatidylcholine (DPPC) and loaded with purified mite allergens induced a higher specific IgG2a/IgG1 subclass ratio and a reduced cellular infiltration with eosinophils compared to allergen adsorbed on alum, while IgE levels were not elevated. 67 Testing differently charged liposomes for induction of immune responses in mice revealed the highest IgG titers (no specific subclasses are shown) and lowest IgE levels with positively charged liposomes compared to the neutral and negative ones. 68 A very recent report demonstrated reduced serum IgE and intranasal mucus production together with a shift in the cytokine profile from Th2 toward Th1 and Treg after AIT of sensitized mice with liposome-entrapped cat allergens. 69 A decreased IgE level could also be observed after intragastrical administration of OVA-loaded liposomes into presensitized mice, but compared to application of free OVA, there was no additional benefit for the liposomal preparations. 70 Application of allergen-loaded liposomes in human clinical trials of AIT revealed that liposomal formulations were slightly more effective than adsorbed extracts, but less favorable systemic safety and complex manufacturing process led to the conclusion that liposomes are not suited for AIT. 71 However, another study with 55 asthmatic patients reported no side-effects and reduced symptom and medication scores by at least 60% in nearly half of the patients vaccinated with a liposome-encapsulated house dust mite allergen compared to 12% in the placebo group and a decreased organ sensitivity measured by skin prick test, intradermal testing, and bronchial challenge.
Accordingly, specific IgG, IgG1, and especially IgG4 production was augmented during the therapy, while no change in specific IgE production was observed. 72 Preventive as well as therapeutic vaccination of mice with oligomannose-coated liposomes led to decreased IL-4 and IL-5 production and decreased specific IgE and IgG1 levels, while specific IgG2a
and IFN-c were enhanced. 73 The same modified liposomes were also able to induce CD8 + -Treg leading to the suppression of allergic diarrhea in a murine food allergy model. Additionally, allergen-specific IgE was reduced and IL-10, IgG1, IgG2a, and soluble IgA were elevated. 74 In another murine study, two different liposome-adjuvanted cockroach allergy vaccines were compared. The authors could show that liposomes loaded with the refined protein Per a 9 were superior to alleviate airway inflammation than crude extract-loaded liposomes. 75 Immunostimulatory complexes of liposomes, CpG-DNA, and allergen were used in AIT of dogs with atopic dermatitis which resulted in an improvement of the pruritus score and a decrease in IL-4 mRNA expression in PBMC compared to the pretreatment values while IFN-c and IL-10 mRNA as well as medication score did not change. 76 Treatment of chronic rhinitis in cats with liposome-IL-2 DNA complexes showed significant improvement in frequency of sneezing, but no differences in cytokine profile. The authors further demonstrated that chronic rhinitis in cats is not a disease with a Th2 cytokine bias. 77 AIT of presensitized mice with liposome-protamine-
DNA NPs resulted in a reduction of IgE as well as induction of
IgG2a, IFN-c, and T-bet together with higher lymphoproliferative responses. 78 In another approach, OVA was covalently coupled to distearoylphosphatidylcholine (DSPC)-cholesterol liposomes. When presensitized mice were treated with these liposomes, OVA-specific IgE was strongly suppressed whereas IgG1 levels were not affected, but also decreased using high-density OVA liposomes. Additional loading of these liposomes with doxorubicin further reduced OVAspecific IgE probably by eradication of OVA-specific B cells in the spleen. 79 Finally, multilamellar, small unilamellar, and reversed phase vesicle liposomes were analyzed regarding encapsulation efficiency of house dust mite allergens, but no cellular tests were performed. 80 
| Virus-like particles
Virus-like particles (VLPs) have been applied as adjuvants or drug delivery systems. 81, 82 In a placebo-controlled, double-blind, randomized trial, house dust mite allergic patients were treated with VLPs consisting of bacteriophage Qß coat protein associated with CpG-ODN resulting in lower rhinoconjunctivitis symptoms and better quality-of-life score. Additionally, a 10-fold increase in allergen tolerance was demonstrated by conjunctival provocation test. 83 In another clinical trial, the same VLPs were used as an adjuvant for ATI with house dust mite allergen extract. Symptoms of rhinitis and allergic asthma were significantly reduced and humoral response was shifted toward Th1. 84 In mice, a single sc vaccination of Fel d 1 coupled to bacteriophage Qß-derived VLPs led to protection against type I allergic reactions without inducing local or systemic reactions.
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Additionally, the allergen-coupled VLPs did not lead to degranulation of human basophils in vitro. 85 Immunization of mice with adeno- Poly(alkyl cyanoacrylate), which is degradable under acidic conditions, is also known in drug delivery. Table 2 ).
| Polymer NPs
Dendrimers, which are perfectly branched, tree-like polymer structures with a high number of end groups that can be used for conjugation, were investigated as drug delivery systems. 90 Vaccination of mice with a dendrimer made from poly(propylene imine) loaded with Bet v 1a pDNA resulted in decreased specific IgE combined with an enhanced Th1 response. 91 Furthermore, guanidine-terminated dendrimers containing an amyloid-promoting OVA peptide effectively associated with RAW264 cells, but unfortunately no further immunological tests were shown. In both cases, it is likely that the cargo was transported by several molecules that assemble to form NPs, but not by one dendrimer molecule itself. 92 Preventive and therapeutic application of CpG coupled with poly(propylene sulfide) NPs enhanced recruitment of activated DCs and led to a shift toward Th1 immunity which was superior compared to free CpG. 93 Garaczi et al. 94 assembled NPs by mixing poly(ethylene imine) with OVA pDNA. In a murine allergic rhinitis model, topical administration of these NPs reduced nasal symptoms of about 50% and induced a balanced Th1/Th2
F I G U R E 3 Overview of nonbiodegradable nanostructures used in allergen-specific immunotherapy (AIT)
T A B L E 2 Overview of nonbiodegradable nanoparticles (NPs) for allergen-specific immunotherapy (AIT) OVA plus LPS-entrapped NPs. 97, 98 Poloxamine (copolymers of ethylene oxide and propylene oxide) nanospheres loaded with Der f 1 plasmid were tested regarding therapeutic effect on asthmatic mice, and a reduction of airway hyperreactivity together with a decrease in inflammatory cytokines in the BAL could be observed. 99 An interesting method to prepare nano-sized peptide-surfactant complexes by solid-in-oil nanodispersions with proteins was reported by two groups demonstrating facilitated skin penetration of the allergen peptide and suppressed IgE levels in mice. 100, 101 Oral treatment of presensitized guinea pigs with a copolymer of methacrylic acid and methylmethacrylate (Eudragit L-100), which was used to give an enteric coating of grass pollen allergen extract in order to protect it against gastric degradation, induced increased secondary antibody responses compared to aqueous presentation. 102 Oral treatment of ragweed-sensitized patients with ragweed pollen extract encapsulated in polymethacrylic acid copolymer NPs led to the production of high allergen-specific IgG and IgG4 titers while specific IgE antibodies were not increased. The therapy was possible without side-effects and decreased symptomatic medication. 103 The same NP system was applied for encapsulation of timothy grass pollen. In addition to decreased medication and symptom scores, the authors discovered a reduced allergen-specific T-cell proliferation and IL-5 mRNA production in vitro. 104 The most prominent synthetic water-soluble polymer is poly (ethylene glycol) (PEG), an aliphatic polyether, that is widely used in pharmaceutical applications. PEG is often described as the "gold standard" for biomedical applications and obtained this status because of its unique properties. 105 As PEG is a nonbiodegradable polymer, cleavage sites need to be introduced for controlled delivery of proteins by PEG-based NP in AIT. To this end, acid-labile PEGmacromonomers that degrade at pH 5 (physiological pH inside the endolysosome) were synthetized by Pohlit et al. 106 Encapsulation of allergens into these NPs resulted in targeted delivery and induction of T-cell proliferation concurrently with allergen shielding from recognition by IgE antibodies in human in vitro experiments.
| Carbon-based NPs
Carbon nanotubes are extensively investigated in the field of drug delivery, especially in tumor targeting and as biosensors. The toxicity and influence on the immune system are controversially discussed. 107 Investigation of the immunomodulatory activity of multiwalled carbon nanotubes in PBMC from healthy and allergic donors revealed that they may either promote or suppress immune responses, and may therefore be suitable adjuvants. 108 In a mouse model of asthma, however, allergen-induced systemic immune responses and airway inflammation were worsened by such nanotubes. 109 For more than two decades, fullerenes, a carbon allotrope, have been investigated for possible application in biotechnology and medicine. Ryan et al. 110 effects. 113 Intranasal administration of gold NPs prior to allergen challenge inhibited accumulation of inflammatory cells, mucus production, airway hyperreactivity, and production of pro-inflammatory cytokines and reactive oxygen species in OVA-sensitized mice. 114 Magnetic NPs combine the advantage of good detectability for imaging purposes and drug delivery and gained attention, for example, in hyperthermia-based therapy. 115 Marengo et al. 116 presented a possible delivery platform for AIT made of dextran-coated magnetic NPs conjugated with bovine b-lactoglobulin or ovomucoid. They observed higher uptake of the conjugated compared to nonconjugated NPs by human monocytes and confirmed internalization by confocal laser scanning microscopy. Nanodecoys consist of a solid core made of hydroxyl apatite which provides structural stability and a carbohydrate coating to which peptides and proteins can adsorb. Presensitized mice treated with ultrafine nanodecoys coated with trehalose and adsorbed by ovalbumin, also called aquasomes, showed lower levels of IgE and serum histamine, higher survival rate, and reduced symptoms during induction of anaphylaxis. 
| SUMMARY AND OUTLOOK
Although it is the only disease-modifying therapy for allergic rhinoconjunctivitis and asthma at present, AIT suffers from potential systemic side-effects mainly occurring during sc treatment. Prevention of these side-effects resulting in safer therapy as well as a more efficient treatment-even though there is no reliable biomarker predictive of AIT efficacy so far-is a main goal for improving strategies in AIT. Approaches to achieve this goal include a molecular-based diagnosis to refine the prescription, and a therapy with physically adsorbed allergens as (semi-) depot extracts, modified allergens like allergoids or hypoallergenic recombinant allergens or peptides or coadministration of anti-IgE antibodies. 120 Another concept as an alter- 
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